These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

9400 related articles for article (PubMed ID: 18975677)

  • 1. Improving quality assurance for assembled COMS eye plaques using a pinhole gamma camera.
    Beiki-Ardakani A; Jezioranski J; Jaffray DA; Young I
    Med Phys; 2008 Oct; 35(10):4318-23. PubMed ID: 18975677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An improved treatment planning and quality assurance process for Collaborative Ocular Melanoma Study eye plaque brachytherapy.
    Weersink RA; Patterson S; Ballantyne H; Di Tomasso A; Borg J; Vitkin A; Rink A; Beiki-Ardakani A
    Brachytherapy; 2019; 18(5):658-667. PubMed ID: 31235445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and dosimetric considerations of a modified COMS plaque: the reusable "seed-guide" insert.
    Astrahan MA; Szechter A; Finger PT
    Med Phys; 2005 Aug; 32(8):2706-16. PubMed ID: 16193802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of material heterogeneity dosimetric effects using radiochromic film for COMS eye plaques loaded with (125)I seeds (model I25.S16).
    Acar H; Chiu-Tsao ST; Ozbay I; Kemikler G; Tuncer S
    Med Phys; 2013 Jan; 40(1):011708. PubMed ID: 23298078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delivered dose uncertainty analysis at the tumor apex for ocular brachytherapy.
    Morrison H; Menon G; Larocque MP; Jans HS; Weis E; Sloboda RS
    Med Phys; 2016 Aug; 43(8):4891. PubMed ID: 27487906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monte Carlo dosimetry for 125I and 103Pd eye plaque brachytherapy with various seed models.
    Thomson RM; Rogers DW
    Med Phys; 2010 Jan; 37(1):368-76. PubMed ID: 20175499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosimetry of (125)I and (103)Pd COMS eye plaques for intraocular tumors: report of Task Group 129 by the AAPM and ABS.
    Chiu-Tsao ST; Astrahan MA; Finger PT; Followill DS; Meigooni AS; Melhus CS; Mourtada F; Napolitano ME; Nath R; Rivard MJ; Rogers DW; Thomson RM
    Med Phys; 2012 Oct; 39(10):6161-84. PubMed ID: 23039655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of 16 mm OSU-Nag and COMS eye plaques.
    Zhang H; Davidorf F; Qi Y
    J Appl Clin Med Phys; 2012 May; 13(3):3632. PubMed ID: 22584165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monte Carlo simulation of COMS ophthalmic applicators loaded with Bebig I25.S16 seeds and comparison with planning system predictions.
    Miras H; Terrón JA; Lallena AM
    Phys Med; 2013 Nov; 29(6):670-6. PubMed ID: 22858007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monte Carlo dosimetry for 125I and 103Pd eye plaque brachytherapy.
    Thomson RM; Taylor RE; Rogers DW
    Med Phys; 2008 Dec; 35(12):5530-43. PubMed ID: 19175111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved treatment planning for COMS eye plaques.
    Astrahan MA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1227-42. PubMed ID: 15752905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A practical approach to estimating optic disc dose and macula dose without treatment planning in ocular brachytherapy using
    Lee YC; Lin SC; Kim Y
    Radiat Oncol; 2018 Nov; 13(1):221. PubMed ID: 30424782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monte Carlo dosimetry for 103Pd, 125I, and 131Cs ocular brachytherapy with various plaque models using an eye phantom.
    Lesperance M; Martinov M; Thomson RM
    Med Phys; 2014 Mar; 41(3):031706. PubMed ID: 24593710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COMS eye plaque brachytherapy dosimetry simulations for 103Pd, 125I, and 131Cs.
    Melhus CS; Rivard MJ
    Med Phys; 2008 Jul; 35(7):3364-71. PubMed ID: 18697560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental validation of a new COMS-like 24 mm eye plaque for the treatment of large ocular melanoma tumors.
    McCauley Cutsinger S; Forsman R; Corner S; Deufel CL
    Brachytherapy; 2019; 18(6):890-897. PubMed ID: 31444131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Method for verifying the air kerma strength of I-125 plaques for the treatment of ocular melanoma.
    Zimmermann LW; Wilkinson DA
    J Appl Clin Med Phys; 2014 Jul; 15(4):4880. PubMed ID: 25207419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dosimetric comparison of circular Eye Physics and Collaborative Ocular Melanoma Study plaques to treat uveal melanoma.
    Dean MK; Studenski MT; Paez-Escamilla MA; Walter SD; Kwon D; Markoe AM; Harbour JW; Samuels SE
    Brachytherapy; 2019; 18(3):404-410. PubMed ID: 30797699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial evaluation of Advanced Collapsed cone Engine dose calculations in water medium for I-125 seeds and COMS eye plaques.
    Morrison H; Menon G; Larocque MP; van Veelen B; Niatsetski Y; Weis E; Sloboda RS
    Med Phys; 2018 Mar; 45(3):1276-1286. PubMed ID: 29383721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Model-based dose calculations for COMS eye plaque brachytherapy using an anatomically realistic eye phantom.
    Lesperance M; Inglis-Whalen M; Thomson RM
    Med Phys; 2014 Feb; 41(2):021717. PubMed ID: 24506608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigating the dosimetric impact of seed location uncertainties in Collaborative Ocular Melanoma Study-based eye plaques.
    Johnson JE; Deufel CL; Furutani KM
    Brachytherapy; 2016; 15(5):661-8. PubMed ID: 27475484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 470.